Journal article
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Abstract
The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was demonstrated for 554 and 400 days maximum …
Authors
Awasthi R; Pacaud L; Waldron E; Tam CS; Jäger U; Borchmann P; Jaglowski S; Foley SR; van Besien K; Wagner-Johnston ND
Journal
Blood Advances, Vol. 4, No. 3, pp. 560–572
Publisher
American Society of Hematology
Publication Date
February 11, 2020
DOI
10.1182/bloodadvances.2019000525
ISSN
2473-9529